Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends
Jason Boer, Ellen A. Cannady, Filip Cuyckens, Ulrike Glaenzel et autres
0 citationsClinical Pharmacology & Therapeutics
Cathy Cantalloube
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
32Publications signalées
518Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Malaria Research and ControlEpilepsy research and treatmentDrug Transport and Resistance MechanismsFerrocene Chemistry and ApplicationsCalpain Protease Function and Regulation
Publications récentes
Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework
Filip Cuyckens, W.‐S. Li, Adam Auclair, Kenneth C. Cassidy et autres
1 citationClinical Pharmacology & Therapeutics
Investigating belumosudil in children with refractory moderate-to-severe chronic graft-versus-host disease: Design of a phase 1/2 study
Kirk R. Schultz, Adriana Balduzzi, Marta González‐Vicent, Muna Qayed et autres
0 citationsBlood
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
Joaquina Baranda, Debbie Robbrecht, Ryan J. Sullivan, Bernard Doger et autres
10 citationsClinical and Translational Science
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
Agnès Hincelin-Méry, X. Nicolas, Cathy Cantalloube, Robert J. Pomponio et autres
44 citationsClinical and Translational Science
First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants (S46.005)
Agnès Hincelin-Méry, Pascale Lewanczyk, Cathy Cantalloube, X. Nicolas et autres
2 citationsNeurology
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents
Jidong Zhang, Christine Lair, Kwame Amaning, María Belén Pascual Barrio et autres
24 citationsCell
Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria
Adama Gansané, Moussa Lingani, Adoke Yeka, Alain Nahum et autres
19 citationsMalaria Journal
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria
Adoke Yeka, Rella Zoleko‐Manego, Serge Ouoba, Alfred B. Tiono et autres
61 citationsMalaria Journal
Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria
Christian Supan, Ghyslain Mombo‐Ngoma, Maryvonne Kombila, Carmen L. Ospina Salazar et autres
30 citationsAmerican Journal of Tropical Medicine and Hygiene
Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients
Jana Held, Christian Supan, Carmen L. Ospina Salazar, Halidou Tinto et autres
11 citationsMalaria Journal
SAFETY AND EFFICACY OF SAR97276A FOR TREATING MALARIA: TWO OPEN-LABEL MULTICENTER PHASE II CLINICAL STUDIES IN AFRICAN CHILDREN AND ADULTS
Jana Held, Christian Supan, Carmen L. Ospina Salazar, Halidou Tinto et autres
0 citationsBMJ Global Health
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.